The technological innovations in drug discovery have led to the development of larger, more complex and more hydrophobic compounds as lead candidates and active pharmaceutical ingredients. According to an estimate, 40% of the drugs in market and 90% of the new chemical entities are considered hydrophobic . These molecules require specialized processing and safe vehicles for solubilisation, including problems at various levels from discovery to processing and formulations development . However, many vehicles available do either not have an ideal safety profile, e.g. Cremophor EL (CrEL) for paclitaxel (PTX) administration or are not as good solubilizers as would be desired. Even with the premedication including corticosteroids and anti-histamines, CrEL induced hypersensitivity reactions are commonly observed and most vehicles/excipients do not allow for solubilization of more than 20 wt. -25 wt.% and the overall increase in apparent solubility is limited. Thus, for the delivery of these agents, there is clear need to find alternative formulations and vehicles.